Ticagrelor Monotherapy Reduces Bleeding Risk Following PCI in CKD
Ticagrelor monotherapy more effectively reduced risk for bleeding events following PCI among patients with CKD but had little effect on ischemic events.
Chronic Kidney Disease
SHPT, Hyperphosphatemia Linked to CV Event Incidence in Chronic Kidney Disease
The primary objective of this study was to assess whether the potential independent effects of secondary hyperparathyroidism on the risk for CKD progression and cardiovascular event incidence in CKD patients act as effect modifiers.
Guidelines To Lower Systolic Blood Pressure For Adults With Chronic Kidney Disease
69.5 percent of adults with CKD eligible for BP lowering according to 2021 KDIGO guideline versus 49.8 percent with 2012 guideline
- Loading...
Loading...
Next post in Prevention
Loading... 
Loading...